FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
1/7/2018
0:00
NaN:NaN:NaN
Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer.
Released on December 21, 2017
More episodes from "FDA Drug Information Updates"
Don't miss an episode of “FDA Drug Information Updates” and subscribe to it in the GetPodcast app.